| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_859e9e735009138cdc05c7a45525de7d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-686
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6804
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2531-113 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155 |
| filingDate |
2015-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f043fbb8140e56de44dd877f7577f3be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2b13da0fd8ad7fda990cbccc53dbe3c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9edbb0aba7684bfbbaf15d17642a7ec8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdfbb1dd9eba7d5f4468d96289efb519 |
| publicationDate |
2017-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2626670-C2 |
| titleOfInvention |
Method prediction of therapy effeciency for patients with type 2 sugar diabetes |
| abstract |
FIELD: medicine. n SUBSTANCE: peripheral venous blood sampling and DNA extraction are performed. Prior to metformin appointment, the level of glycated hemoglobin and the level of C-peptide are determined, after which genetic typing of the single nucleotide polymorphism of the rs2070744 gene of endothelial nitric oxide synthase C786T is performed. When the CC or CT haplotype is isolated, efficiency of monotherapy with metformin 850 mg twice a day and a decrease in the glycated hemoglobin level and an increase in the C peptide level relative to the baseline levels for 3 months is predicted. n EFFECT: improved prediction accuracy. n 2 dwg, 1 tbl, 3 ex |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2694505-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2746830-C1 |
| priorityDate |
2015-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |